Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s disease despite improving biomarkers. The trials were global, involved ...
Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...
(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its ...
Hosted on MSN
Novo Nordisk’s Semaglutide Falls Short In Alzheimer’s Study, Showing No Slowing Of Disease
Alzheimer’s patients have received discouraging news after the release of results from a major study. Novo Nordisk confirmed that its Alzheimer’s treatment did not show a “statistically significant” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback